Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025

Efficacy of immunotherapy in older patients with triple-negative breast cancer: a systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCarrie ShaMLMarie LiuASAshley Schreier

Discussion

Loading...

Member takes

Overview

Systematic review finds limited efficacy of immune checkpoint inhibitors in patients aged 65 and older, highlighting research gaps.

Key Points

  • Limited data from RCTs show immune checkpoint inhibitors have unclear efficacy for older patients with triple-negative breast cancer.
  • Only four RCTs provided results for patients aged 65 and older, representing 18.7% of the total participants.
  • Key studies such as KEYNOTE 355 and IMPASSION 130 indicate varying outcomes but lack statistical significance for older patients.
  • The findings emphasize the urgent need for further research on immunotherapy efficacy in older triple-negative breast cancer patients.

Cite This Study

Sha et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfd60https://doi.org/10.21203/rs.3.rs-7024355/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC2025
  2. 2Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor.2025
  3. 3Age-related survival disparities in advanced renal cell carcinoma following immune checkpoint inhibitor adoption using SEER and meta-analysis2025
  4. 4Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland2025
  5. 5The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis2025